Copyright Reports & Markets. All rights reserved.

Global and China Tumor Biomarker Test Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Tumor Biomarker Test Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Prostate Specific Antigen Tests
    • 1.2.3 CTC Tests
    • 1.2.4 Alpha-Fetoprotein (AFP) Tests
    • 1.2.5 CA Test
    • 1.2.6 HER2 Tests
    • 1.2.7 BRCA Test
    • 1.2.8 Anaplastic Lymphoma Kinase (ALK) Tests
    • 1.2.9 EGFR Mutation Tests
    • 1.2.10 KRAS Test
    • 1.2.11 Others
  • 1.3 Market by Application
    • 1.3.1 Global Tumor Biomarker Test Market Share by Application: 2020 VS 2026
    • 1.3.2 Lung cancer
    • 1.3.3 Breast cancer
    • 1.3.4 Colorectal
    • 1.3.5 Prostate Cancer
    • 1.3.6 Blood Cancer
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Tumor Biomarker Test Market Perspective (2015-2026)
  • 2.2 Global Tumor Biomarker Test Growth Trends by Regions
    • 2.2.1 Tumor Biomarker Test Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Tumor Biomarker Test Historic Market Share by Regions (2015-2020)
    • 2.2.3 Tumor Biomarker Test Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Tumor Biomarker Test Players by Market Size
    • 3.1.1 Global Top Tumor Biomarker Test Players by Revenue (2015-2020)
    • 3.1.2 Global Tumor Biomarker Test Revenue Market Share by Players (2015-2020)
  • 3.2 Global Tumor Biomarker Test Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Tumor Biomarker Test Revenue
  • 3.4 Global Tumor Biomarker Test Market Concentration Ratio
    • 3.4.1 Global Tumor Biomarker Test Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Tumor Biomarker Test Revenue in 2019
  • 3.5 Key Players Tumor Biomarker Test Area Served
  • 3.6 Key Players Tumor Biomarker Test Product Solution and Service
  • 3.7 Date of Enter into Tumor Biomarker Test Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Biomarker Test Breakdown Data by Type (2015-2026)

  • 4.1 Global Tumor Biomarker Test Historic Market Size by Type (2015-2020)
  • 4.2 Global Tumor Biomarker Test Forecasted Market Size by Type (2021-2026)

5 Tumor Biomarker Test Breakdown Data by Application (2015-2026)

  • 5.1 Global Tumor Biomarker Test Historic Market Size by Application (2015-2020)
  • 5.2 Global Tumor Biomarker Test Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Tumor Biomarker Test Market Size (2015-2026)
  • 6.2 North America Tumor Biomarker Test Market Size by Type (2015-2020)
  • 6.3 North America Tumor Biomarker Test Market Size by Application (2015-2020)
  • 6.4 North America Tumor Biomarker Test Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Tumor Biomarker Test Market Size (2015-2026)
  • 7.2 Europe Tumor Biomarker Test Market Size by Type (2015-2020)
  • 7.3 Europe Tumor Biomarker Test Market Size by Application (2015-2020)
  • 7.4 Europe Tumor Biomarker Test Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Tumor Biomarker Test Market Size (2015-2026)
  • 8.2 China Tumor Biomarker Test Market Size by Type (2015-2020)
  • 8.3 China Tumor Biomarker Test Market Size by Application (2015-2020)
  • 8.4 China Tumor Biomarker Test Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Tumor Biomarker Test Market Size (2015-2026)
  • 9.2 Japan Tumor Biomarker Test Market Size by Type (2015-2020)
  • 9.3 Japan Tumor Biomarker Test Market Size by Application (2015-2020)
  • 9.4 Japan Tumor Biomarker Test Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Tumor Biomarker Test Market Size (2015-2026)
  • 10.2 Southeast Asia Tumor Biomarker Test Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Tumor Biomarker Test Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Tumor Biomarker Test Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Abbott Laboratories, Inc.
    • 11.1.1 Abbott Laboratories, Inc. Company Details
    • 11.1.2 Abbott Laboratories, Inc. Business Overview
    • 11.1.3 Abbott Laboratories, Inc. Tumor Biomarker Test Introduction
    • 11.1.4 Abbott Laboratories, Inc. Revenue in Tumor Biomarker Test Business (2015-2020))
    • 11.1.5 Abbott Laboratories, Inc. Recent Development
  • 11.2 Agilent Technologies
    • 11.2.1 Agilent Technologies Company Details
    • 11.2.2 Agilent Technologies Business Overview
    • 11.2.3 Agilent Technologies Tumor Biomarker Test Introduction
    • 11.2.4 Agilent Technologies Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.2.5 Agilent Technologies Recent Development
  • 11.3 AstraZeneca
    • 11.3.1 AstraZeneca Company Details
    • 11.3.2 AstraZeneca Business Overview
    • 11.3.3 AstraZeneca Tumor Biomarker Test Introduction
    • 11.3.4 AstraZeneca Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.3.5 AstraZeneca Recent Development
  • 11.4 Becton Dickinson & Co.
    • 11.4.1 Becton Dickinson & Co. Company Details
    • 11.4.2 Becton Dickinson & Co. Business Overview
    • 11.4.3 Becton Dickinson & Co. Tumor Biomarker Test Introduction
    • 11.4.4 Becton Dickinson & Co. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.4.5 Becton Dickinson & Co. Recent Development
  • 11.5 Biocept Inc.
    • 11.5.1 Biocept Inc. Company Details
    • 11.5.2 Biocept Inc. Business Overview
    • 11.5.3 Biocept Inc. Tumor Biomarker Test Introduction
    • 11.5.4 Biocept Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.5.5 Biocept Inc. Recent Development
  • 11.6 Cancer Genetics Inc.
    • 11.6.1 Cancer Genetics Inc. Company Details
    • 11.6.2 Cancer Genetics Inc. Business Overview
    • 11.6.3 Cancer Genetics Inc. Tumor Biomarker Test Introduction
    • 11.6.4 Cancer Genetics Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.6.5 Cancer Genetics Inc. Recent Development
  • 11.7 Danaher Corporation
    • 11.7.1 Danaher Corporation Company Details
    • 11.7.2 Danaher Corporation Business Overview
    • 11.7.3 Danaher Corporation Tumor Biomarker Test Introduction
    • 11.7.4 Danaher Corporation Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.7.5 Danaher Corporation Recent Development
  • 11.8 Foundation Medicine Inc.
    • 11.8.1 Foundation Medicine Inc. Company Details
    • 11.8.2 Foundation Medicine Inc. Business Overview
    • 11.8.3 Foundation Medicine Inc. Tumor Biomarker Test Introduction
    • 11.8.4 Foundation Medicine Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.8.5 Foundation Medicine Inc. Recent Development
  • 11.9 Illumina Inc.
    • 11.9.1 Illumina Inc. Company Details
    • 11.9.2 Illumina Inc. Business Overview
    • 11.9.3 Illumina Inc. Tumor Biomarker Test Introduction
    • 11.9.4 Illumina Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.9.5 Illumina Inc. Recent Development
  • 11.10 LabCorp Of America Holdings
    • 11.10.1 LabCorp Of America Holdings Company Details
    • 11.10.2 LabCorp Of America Holdings Business Overview
    • 11.10.3 LabCorp Of America Holdings Tumor Biomarker Test Introduction
    • 11.10.4 LabCorp Of America Holdings Revenue in Tumor Biomarker Test Business (2015-2020)
    • 11.10.5 LabCorp Of America Holdings Recent Development
  • 11.11 Luminex Corporation
    • 10.11.1 Luminex Corporation Company Details
    • 10.11.2 Luminex Corporation Business Overview
    • 10.11.3 Luminex Corporation Tumor Biomarker Test Introduction
    • 10.11.4 Luminex Corporation Revenue in Tumor Biomarker Test Business (2015-2020)
    • 10.11.5 Luminex Corporation Recent Development
  • 11.12 Myriad Genetics Inc.
    • 10.12.1 Myriad Genetics Inc. Company Details
    • 10.12.2 Myriad Genetics Inc. Business Overview
    • 10.12.3 Myriad Genetics Inc. Tumor Biomarker Test Introduction
    • 10.12.4 Myriad Genetics Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 10.12.5 Myriad Genetics Inc. Recent Development
  • 11.13 NanoString Technologies Inc.
    • 10.13.1 NanoString Technologies Inc. Company Details
    • 10.13.2 NanoString Technologies Inc. Business Overview
    • 10.13.3 NanoString Technologies Inc. Tumor Biomarker Test Introduction
    • 10.13.4 NanoString Technologies Inc. Revenue in Tumor Biomarker Test Business (2015-2020)
    • 10.13.5 NanoString Technologies Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Tumor Biomarker Test Scope and Market Size
    Tumor Biomarker Test market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Biomarker Test market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Prostate Specific Antigen Tests
    CTC Tests
    Alpha-Fetoprotein (AFP) Tests
    CA Test
    HER2 Tests
    BRCA Test
    Anaplastic Lymphoma Kinase (ALK) Tests
    EGFR Mutation Tests
    KRAS Test
    Others

    Market segment by Application, split into
    Lung cancer
    Breast cancer
    Colorectal
    Prostate Cancer
    Blood Cancer

    Based on regional and country-level analysis, the Tumor Biomarker Test market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Tumor Biomarker Test market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Abbott Laboratories, Inc.
    Agilent Technologies
    AstraZeneca
    Becton Dickinson & Co.
    Biocept Inc.
    Cancer Genetics Inc.
    Danaher Corporation
    Foundation Medicine Inc.
    Illumina Inc.
    LabCorp Of America Holdings
    Luminex Corporation
    Myriad Genetics Inc.
    NanoString Technologies Inc.

    Buy now